Medical cannabis has become a defining issue in Nebraska’s 2026 congressional races. Candidates are now openly campaigning on securing Nebraska medical marijuana protections, arguing that federal law should reinforce, not undermine, what voters approved in 2024.
At the center of the dispute is Nebraska’s exclusion from a long-standing federal safeguard that protects most state medical marijuana programs from federal interference. Advocates say that omission is not minor. It leaves patients operating without the same protections enjoyed in nearly every other medical cannabis state.
Key Takeaways
- Nebraska is excluded from the federal Rohrabacher–Blumenauer appropriations rider that shields most state medical marijuana programs.
- Congressional candidates have pledged to strengthen Nebraska medical marijuana protections through federal legislation.
- 71 percent of Nebraska voters approved medical marijuana access in 2024.
- Advocates warn that without federal alignment, patients face continued legal uncertainty.
The Federal Rider Nebraska Was Left Out Of
Since 2014, Congress has passed a budget amendment commonly known as the Rohrabacher–Blumenauer amendment, later renamed the Joyce amendment. The provision prohibits the U.S. Department of Justice from using federal funds to interfere with state medical marijuana laws.
The rider must be renewed annually through appropriations legislation. When included, it effectively prevents federal prosecutors from targeting patients and providers who comply with state medical cannabis programs.
Nearly every state with legal medical marijuana is covered.
Nebraska is not.
That absence has raised alarms among advocates who argue that Nebraska medical marijuana protections are incomplete without inclusion in the federal spending safeguard. While federal enforcement against state programs has been rare in recent years, the legal authority technically remains intact when a state is not named in the rider.
For patients, that distinction matters.
Candidates Pledge to Strengthen Nebraska Medical Marijuana Protections
During a webinar hosted by Americans for Safe Access and Nebraskans for Medical Marijuana, State Sen. John Cavanaugh and U.S. Senate candidate Dan Osborn committed to pursuing federal solutions.
Both signed the Compassionate Pledge, which calls on candidates to cosponsor legislation establishing a national medical cannabis program under the U.S. Department of Health and Human Services.
Steph Sherer, founder and executive director of Americans for Safe Access, framed the stakes clearly:
“The next Congress will decide whether cannabis is fully integrated into American healthcare—or left vulnerable to political rollback impacting the millions of Americans… who rely on cannabinoid medicines.”
Cavanaugh emphasized that Nebraska voters have already spoken. In 2024, 71 percent approved medical marijuana access. He argued that Congress should not allow federal technicalities to erode that mandate.
Osborn echoed that message, describing the issue as one of representation. He pointed to veterans, chronic pain patients and families managing severe medical conditions, saying elected officials must reflect voter decisions rather than resist them.
Their campaigns now center in part on expanding Nebraska medical marijuana protections beyond temporary budget language and into durable federal statute.
Voter Approval Collides With Federal Prohibition
Nebraska’s medical marijuana approval was decisive. Implementation, however, has been complicated by political resistance and structural delays. The state’s Medical Cannabis Commission continues to face scrutiny, and leadership changes have added further instability.
Layered on top of that uncertainty is federal prohibition.
Cannabis remains classified as a Schedule I substance under federal law. Although the Justice Department has largely deferred to state programs when the appropriations rider is in effect, that protection is not permanent and must be renewed each year.
Without guaranteed Nebraska medical marijuana protections at the federal level, patients may worry about risks tied to federal housing, employment or benefits. Even if enforcement remains unlikely, ambiguity creates anxiety.
Crista Eggers, a leading advocate and parent of a child who benefits from cannabis treatment, has argued that Nebraska’s exclusion from the rider leaves families feeling exposed. For them, the issue is not theoretical. It affects real medical decisions.
The Push for a National Medical Cannabis Framework
Both candidates argue that relying on annual budget riders is insufficient. They support broader federal reform that would formally integrate medical cannabis into the healthcare system.
A national program under HHS could establish:
- Consistent safety standards
- Expanded clinical research pathways
- Clear protections for patients following physician recommendations
Supporters say that long-term Nebraska medical marijuana protections will only be secure if federal law changes permanently. Budget riders provide temporary restraint. Statutory reform would provide structural stability.
The debate also reflects a wider national tension. More than three dozen states allow medical marijuana, yet federal law still treats cannabis as prohibited. Nebraska’s current situation highlights that disconnect in a concrete way.
A 2026 Test of Federal-State Alignment
With medical cannabis approved by voters but federal safeguards incomplete, the issue has become a measuring stick for congressional candidates. The 2026 election will determine whether Nebraska gains representation committed to expanding Nebraska medical marijuana protections or maintains a delegation critics say has worked against reform.
The larger question extends beyond Nebraska. As more states adopt medical cannabis programs, pressure continues to build on Congress to reconcile federal prohibition with state law.
For Nebraska patients, the outcome carries immediate consequences. Inclusion in federal protections would reduce uncertainty. Permanent reform would remove it altogether.
Conclusion
The debate over Nebraska medical marijuana protections has evolved from a policy technicality into a central campaign issue. Voters approved medical cannabis access in 2024. Now the focus shifts to whether Congress will align federal law with that decision.
At stake is legal stability for patients, clarity for providers and the broader balance between state authority and federal control. As the 2026 race unfolds, medical marijuana stands as both a healthcare issue and a test of political accountability.
This article is based on publicly available legislative records, court filings, industry reports, and published research as of the publication date. Cannabis laws and regulations change frequently — verify current rules with your state’s regulatory agency.
